For more information on the CDC study

For more information on the CDC study , seeFor more information, consumers and industry can the CFIA at 1-800-442-2342 / TTY call 1-800-465-7735 . People who believe they have experienced symptoms of the disease are encouraged to contact their health care professional .

According to the American Cancer Society, cervical cancer is the second most common form of cancer in women in the world, more than 500,000 women annually during the. Traditional Pap smear has helped to significantly reduce cervical cancer mortality rate, a significant number of women with cervical dysplasia still develop cervical cancer, 000 new cases and 5 Based on this informationUnited States each year, so that no additional critical screening process. OncoFISH cervical cancer is the first to try in combination with the currently used screening tests such as the Pap smear and HPV as a differentiator for physicians to determine which patients may regress, progress progress to cervical cancer. Based on this information, physicians and patients to work too early, personalized treatment plans a better a better chance of survival on the individual needs and ultimately increase target. ‘We are excited to offer our first rare cell-based assay, using proprietary Cell Optics Ikonisys ‘platform that supports the basis for all our next generation of diagnostic tests to introduce, ‘said Dr. Petros Tsipouras, Ikonisys CEO and chairman. ‘Through our novel tests and unique ability to intelligently to ensure digital pathology, Ikonisys advance advance the practice of medicine. Offer offer patients and physicians early and accurate detection, but we are here to help them realize the promise of personalized medicine by practitioners to provide the appropriate treatment of individual risk assessment. ‘.

For additional information you can visitCanadian Institutes of Health Research The CIHR be that Government of Canada on the health research support agency and participates?